Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis

Li et al., Research Square, doi:10.21203/rs.3.rs-119202/v1
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Time to viral- -40% Improvement Relative Risk HCQ for COVID-19  Li et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 37 patients in China Slower viral clearance with HCQ (not stat. sig., p=0.056) c19hcq.org Li et al., Research Square, January 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Small retrospective database analysis of 37 late stage patients hospitalized in an intensive care center in China, not finding a significant difference in viral shedding. Pateints were all in serious condition. There was only one death however the group is not specified. Confounding by indication is likely.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
time to viral-, 40.0% higher, relative time 1.40, p = 0.06, treatment 18, control 19.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 12 Jan 2021, retrospective, database analysis, China, preprint, 5 authors.
This PaperHCQAll
Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis
Hui Li, Min Deng, Jie Wang, Lin Ma, Zheng Yang
doi:10.21203/rs.3.rs-119202/v1
Background There is an urgent need for an effective treatment to cure patients with COVID-19 and reduce the duration of viral shedding. Methods We conducted a retrospective study using data from the electronic medical records of patients with confirmed SARS-CoV-2 infection who were hospitalized in the E1-4 intensive care center of Guanggu Hospital, Wuhan City, Hubei Province, China, from February 11, 2020, to March 23, 2020. According to the diagnostic results, the hospitalized patients were divided into the experimental group treated with hydroxychloroquine (HCQ) or chloroquine (CQ) and the control group only treated with conventional therapy without HCQ or CQ. The main outcome was the clearance rate of SARS-CoV-2. Results A total of 37 patients were evaluated. Eighteen patients were assigned to the HCQ or CQ group, and 19 were assigned to the routine treatment group. Treatment with HCQ or CQ was not associated with a difference from routine treatment in the viral shedding duration (median, 14 days vs. 10 days; hazard ratio for viral shedding, 0.393; 95% confidence interval [CI], 0.151 to 1.022; P=0.056). No significant difference in the viral shedding rate was observed between the groups at any time point (7 days, 14 days, 21 days, 28 days and the end point). Conclusion Although this is a retrospective analysis, the results suggest that treatment with HCQ or CQ had no impact on the duration of viral shedding.
Declaration of competing interests The authors have no conflicts of interest or financial ties to disclose.
References
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2
Sun, Lu, Xu, Understanding of COVID-19 based on current evidence, J
Touret, De Lamballerie, Of chloroquine and COVID-19, J]. Antiviral Res, doi:10.1016/j.antiviral.2020.104762
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2022, 3, 30]], 'date-time': '2022-03-30T14:52:48Z', 'timestamp': 1648651968360}, 'posted': {'date-parts': [[2021, 1, 12]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2021, 1, 12]], 'date-time': '2021-01-12T00:00:00Z', 'timestamp': 1610409600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 12, 1]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p><jats:bold>Background </jats:bold>There is an urgent need for an effective ' 'treatment to cure patients with COVID-19 and reduce the duration of viral shedding. ' '<jats:bold>Methods </jats:bold>We conducted a retrospective study using data from the ' 'electronic medical records of patients with confirmed SARS-CoV-2 infection who were ' 'hospitalized in the E1-4 intensive care center of Guanggu Hospital, Wuhan City, Hubei ' 'Province, China, from February 11, 2020, to March 23, 2020. According to the diagnostic ' 'results, the hospitalized patients were divided into the experimental group treated with ' 'hydroxychloroquine (HCQ) or chloroquine (CQ) and the control group only treated with ' 'conventional therapy without HCQ or CQ. The main outcome was the clearance rate of ' 'SARS-CoV-2. <jats:bold>Results </jats:bold>A total of 37 patients were evaluated. Eighteen ' 'patients were assigned to the HCQ or CQ group, and 19 were assigned to the routine treatment ' 'group. Treatment with HCQ or CQ was not associated with a difference from routine treatment ' 'in the viral shedding duration (median, 14 days vs. 10 days; hazard ratio for viral shedding, ' '0.393; 95% confidence interval [CI], 0.151 to 1.022; P=0.056). No significant difference in ' 'the viral shedding rate was observed between the groups at any time point (7 days, 14 days, ' '21 days, 28 days and the end point). <jats:bold>Conclusion </jats:bold>Although this is a ' 'retrospective analysis, the results suggest that treatment with HCQ or CQ had no impact on ' 'the duration of viral shedding.</jats:p>', 'DOI': '10.21203/rs.3.rs-119202/v1', 'type': 'posted-content', 'created': {'date-parts': [[2021, 1, 14]], 'date-time': '2021-01-14T20:53:23Z', 'timestamp': 1610657603000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis', 'prefix': '10.21203', 'author': [ { 'given': 'Hui', 'family': 'Li', 'sequence': 'first', 'affiliation': [{'name': 'Hangzhou Red Cross Hospital'}]}, { 'given': 'Min', 'family': 'Deng', 'sequence': 'additional', 'affiliation': [{'name': 'Hangzhou Red Cross Hospital'}]}, { 'given': 'Jie', 'family': 'Wang', 'sequence': 'additional', 'affiliation': [{'name': 'Hangzhou Red Cross Hospital'}]}, { 'given': 'Lin', 'family': 'Ma', 'sequence': 'additional', 'affiliation': [{'name': 'Hangzhou Red Cross Hospital'}]}, { 'given': 'Zheng', 'family': 'Yang', 'sequence': 'additional', 'affiliation': [{'name': 'Hangzhou Red Cross Hospital'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-119202/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-119202/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 17]], 'date-time': '2021-03-17T16:52:36Z', 'timestamp': 1615999956000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-119202/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1, 12]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-119202/v1', 'relation': {}, 'published': {'date-parts': [[2021, 1, 12]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit